Skip to main content

DR Reddys Laboratories LTD (RDY)

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Last price
$15.05
As of

Kresmion compiles this page from RDY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

DR REDDYS LABORATORIES LTD (RDY): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-11-05.

As of . Source: SEC EDGAR filings for RDY. Method and limitations.

COMPANY DOSSIER

See the full RDY dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for RDY on one page. Preview it with sample data, then open it live with a free account.

Preview the RDY dossier

Active events for RDY

FREE, NO ACCOUNT

Every event on RDY, as it fires

You are seeing 5 of 8 events recorded on RDY since 2026-06-01.

The five above landed across 3 days. The other 3 were recorded on 1 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

RDY positions held by the managers we follow (2026Q2)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 256135203 · 2026Q2$106.5M0.15%
MILLENNIUM MANAGEMENT LLC FundCUSIP 256135203 · 2026Q2$6.8M0.00%
D. E. Shaw & Co., Inc. FundCUSIP 256135203 · 2026Q2$1.8M0.00%
CITADEL ADVISORS LLC FundCUSIP 256135203 · 2026Q2$1.1M0.00%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, RDY

More data on RDY

RDY against its peers

RDY's operating margin of 22.1% ranks in the 92nd percentile of 19 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2024-12-31 and 2025-12-31.

MetricRDYPeer medianPercentilen
Revenue FY326B INRn/an/a0
Revenue YoY16.6%2.0%817
Gross margin58.5%55.4%6020
Operating margin22.1%7.5%9319
Net margin17.4%-3.4%8820
Return on equity17.0%-3.5%9217

Peers (21): ELAN, KNSA, INDV, HLN, RGC, HCM, PBH, CURLF, TAK, PRGO, TRLV, ALVO, GTBIF, CRON, ETON, HROW, EVO, AQST, EOLS, TKNO, KMDA. Left out: SGIOF (no annual filing), HYPMY (no annual filing), GALDY (no annual filing), JHPCY (no annual filing). Fiscal periods ending between 2024-12-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (RDY: 20-F), reported in INR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in RDY on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on RDY in the last 180 days.

Upstream: SEC EDGAR filings for RDY

Kresmion, "DR REDDYS LABORATORIES LTD (RDY) institutional holdings and SEC filings", data as of 2026-11-05, https://kresmion.com/research/RDY. Upstream data: SEC EDGAR filings for RDY.

Link to this data (HTML):

<a href="https://kresmion.com/research/RDY">DR REDDYS LABORATORIES LTD (RDY) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow RDY on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to RDY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the RDY dossier
Share

The RDY intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.